An update on novel investigational agents for the treatment of primary biliary cholangitis
Despite advances, challenges remain in treatment personalization, access to new drugs, and identification of robust endpoints beyond ALP normalization, including quality of life improvements. Future directions emphasize a personalized approach, long-term outcome studies, and broader access to effective therapies.
Authors
- Daniela Gabbia (ORCID: https://orcid.org/0000-0003-2247-8227)
- Annarosa Floreani (ORCID: https://orcid.org/0000-0003-2630-7054)
- Sara De Martin (ORCID: https://orcid.org/0000-0001-6398-8237)
Institutions
- University of Padua (IT)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1080/13543784.2025.2573638
- Citations
- 1
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 1.32